Fallopian tube disorder

This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug carboplatin can prevent ovarian, fallopian tube, or primary peritoneal cancer from progressing after a blood test shows it may have returned. The study includes …

This early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…

This study looked at whether giving heated chemotherapy directly into the abdomen during a second-look surgery is possible for people with ovarian, fallopian tube, or peritoneal cancer. Ten participants who had already received standard treatment were enrolled. The goal was to se…

This completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel …

This study tested a new immunotherapy called Olvi-Vec, which uses a modified virus to attack cancer cells, in 46 patients with ovarian cancer that had come back or stopped responding to standard treatments. The goal was to see if the treatment was safe and could slow tumor growth…

This large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…

This phase 2 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help keep cancer from growing in people with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. After initial chemotherapy with paclitaxel, 20 participants received pembrolizuma…

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…

This study tested a new drug, farletuzumab ecteribulin, which targets a protein found on many ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian cancer had stopped responding to platinum-based treatments. The goal was to see if the new drug …

This early-phase trial tested a new treatment called Radspherin for women with ovarian cancer that has returned and spread in the abdomen. Radspherin consists of tiny radioactive particles injected directly into the belly after surgery to remove visible tumors. The study involved…

This study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer…

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This phase II trial tested whether adding metformin, a common diabetes drug, to standard chemotherapy could help control advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside chemotherapy, followed by mai…

This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…

This study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that stopped responding to platinum chemotherapy and had previously taken PARP inhibitors. The goal was to see if the combo could control the cancer for at least 6 months. The…

This early-phase study tested whether adding a new drug called LDE225 to standard chemotherapy (paclitaxel) is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen participants were monitored for side effects and to find the best dose. …

This trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients re…

This study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…

This study tested a new drug called IMP4297 in 93 women with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has come back after at least two prior treatments. The goal was to see if the drug can shrink tumors or slow the cancer's growth. The drug is taken as …

This phase 2 trial tested a drug called mirvetuximab soravtansine in 79 people with recurrent platinum-sensitive ovarian, peritoneal, or fallopian tube cancers that have high levels of a protein called folate receptor-alpha. The drug is given by IV every three weeks. The main goa…

This trial tested whether a less invasive ultrasound-guided drainage procedure works as well as laparoscopic surgery for treating tubo-ovarian abscess. 208 women with uncomplicated abscess were randomly assigned to one of the two procedures, both combined with antibiotics. The ma…

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 alone could shrink tumors and how safe it was. Participants had already tried at least three other…

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also loo…

This early-stage trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. Z-Endoxifen is a direct form of tamoxifen's active ingredient, b…

This study looked at 120 vulnerable women over 70 with advanced ovarian cancer. It compared three chemotherapy plans: standard two-drug therapy every three weeks, a single drug every three weeks, or a weekly two-drug schedule. The goal was to see which plan allowed patients to co…

This study tested whether giving the immunotherapy drug nivolumab directly into the abdomen is safe after extensive surgery and heated chemotherapy (HIPEC) for advanced ovarian cancer. 22 adults with recurrent ovarian, peritoneal, or fallopian tube cancer took part. The goal was …

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This pilot study tested whether adding the immunotherapy drugs nivolumab (with or without ipilimumab) to standard chemotherapy could be safe for people with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. 27 participants received the drug combina…

This study tested whether zafirlukast, an asthma drug, can slow or stop ovarian cancer in people whose only sign of relapse is a rising CA-125 blood marker. Only 5 participants were enrolled. The main goal was to see if the drug could lower CA-125 levels by at least half for a mo…

This study tested two immunotherapy drugs, durvalumab and tremelimumab, given with chemotherapy before and after surgery for advanced ovarian cancer. The goal was to see if this combination is safe and feasible. About 69 women with stage IIIC to IV ovarian cancer took part. The r…

This Phase 1 trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in complete remission. The treatment is made from each patient's unique tumor mutations an…

This early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. …

This study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…

This phase 2 trial tested whether adding an experimental drug (MK-4830) to standard chemotherapy and pembrolizumab (Keytruda) could better shrink high-grade serous ovarian cancer before surgery. 160 participants with stage III or IV disease received either the standard regimen or…

This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after …

This Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the ca…

This Phase 3 trial tested whether adding the experimental drug BD0801 to standard chemotherapy can help women with recurrent ovarian cancer that no longer responds to platinum-based treatments. The study enrolled 421 participants and compared the combination to chemotherapy alone…

This phase II trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with stage IV ovarian cancer. 91 participants received either chemo alone or chemo plus pembrolizumab, followed by surgery. The goal was t…

This early-phase trial tested a new drug, Karonudib, in 63 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body and any …

This study aimed to create a quick, simple test to diagnose tuberculous meningitis (TBM) in children. TBM is a severe form of TB that affects the brain and is hard to detect with current methods, especially in places with limited resources. Researchers tested 51 inflammatory mark…

This study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve su…

This study tested a web-based program to improve quality of life and reduce stress in ovarian cancer survivors. 326 women participated, comparing a mindfulness program to a healthy lifestyle program. The goal was to see if the online programs could help with stress, anxiety, mood…

This study looked at whether a 10-week pelvic physical therapy program is practical for gynecologic cancer survivors who have sexual problems. Twenty survivors were enrolled to see if they could stick with the program and if it improved their sexual function and quality of life. …

This study tested whether adding the drug aprepitant to standard anti-nausea medicine helps women with gynecologic cancers (like ovarian or cervical cancer) who are getting chemotherapy. 143 women took part. The goal was to see if the extra drug could better prevent nausea and vo…

This early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had come back in a limited area. The main goal was to find the safest dose and check for side effects. Researchers also looked a…

This study tested whether giving heated chemotherapy directly into the abdomen during surgery can improve quality of life for people with advanced ovarian, fallopian tube, or peritoneal cancer. Fifty participants received the treatment after standard chemotherapy. Researchers mea…

This study tested a mobile app designed to help doctors keep track of symptoms in women with advanced ovarian cancer. Ten patients used the app, which combined their medical records with regular symptom reports. The goal was to see if this information helped the care team make be…

This study looks at proteins in the blood of women with ovarian, peritoneal, or fallopian tube cancer who are in remission. The goal is to find a protein pattern, or 'fingerprint,' that signals when the cancer might come back. Researchers followed 119 women with stage III or IV c…

This study looked at two ways to help breast and ovarian cancer survivors get genetic counseling: a mailed brochure or a phone call with a health coach. About 668 women took part. The goal was to see which method led more people to actually get genetic counseling or testing. The …

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …

This study looked at how doctors in Russia treat a specific type of ovarian cancer called HRD-positive. Researchers collected information from 414 patients to understand what treatments they received and how they fared. The goal was to describe real-world practice, not to test a …

This study looked back at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as maintenance therapy. Researchers wanted to see how often serious side effects happened and how patients used the drug in real-life UK clinics. No …

This study looked at whether following national guidelines for ovarian cancer surgery is cost-effective. Researchers measured the cost per quality-adjusted life year (QALY) over three years in 200 women with advanced ovarian cancer. The goal was to understand the economic impact …

This study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samp…

This study reviewed medical records of 51 women with ovarian, fallopian tube, or peritoneal cancer who received the drug rucaparib in real-world clinics, not just in strict trials. Researchers looked at patient history, side effects, dosing, and how long the drug kept cancer from…

This study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…

This completed study followed 40 women who had standard surgery for gynecologic cancers (endometrial, cervical, ovarian, or fallopian tube). Researchers measured changes in quality of life and checked for lower limb lymphedema (leg swelling). The goal was to learn how surgery aff…

This study looked at how behavioral factors, hormones, and natural body chemicals might influence tumor growth in ovarian cancer. Researchers studied 613 women with ovarian cancer to understand these connections. The goal was to gather knowledge, not to test a treatment.

This study looked at whether it's possible to give ovarian cancer patients a special nutrition shake for seven days before their surgery. 23 patients took part to see if they would stick with the program. The goal was just to see if the program was doable, not to measure health b…

This study tested whether saliva samples can be used to remotely monitor cytomegalovirus (CMV) infection in people receiving treatment for ovarian cancer. Researchers compared saliva and blood samples from 49 participants, collected either at the clinic or at home. The goal was t…

This study followed 102 women with ovarian, fallopian tube, or endometrial cancer through six cycles of standard chemotherapy (carboplatin and paclitaxel). Researchers measured taste changes, muscle loss, and nutritional decline at the start, halfway, and end of treatment. The go…